Cell and gene therapy (CGT) is an experimental space that has grown exponentially in recent years; the sector received nearly $20bn in funding last year, a 50% increase on the record $13.5bn it saw in 2018.
The UK has had a 20% growth in the number of advanced therapy medicinal product (ATMP) clinical trials, according to a new report from the Cell and Gene Therapy Catapult (CGT Catapult).